gs-1720
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
2
Phase 4
0
Earliest trial started Aug 20, 2024 (NCT06544733)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- IntegraseINHIBITOR
int inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613685 | Phase 2/Phase 3 (Phase 3) | Oct 21, 2024 | Gilead Sciences |
| NCT06544733 | Phase 2/Phase 3 (Phase 3) | Aug 20, 2024 | Gilead Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 2 | 2 | 1 | 2024 |
1 organizations
Page 1 / 1